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ttp://dx.doi.org/10.1016/j.ajpath.2012.11.022The aim of this study was to determine the role of AMP-activated protein kinase (AMPK) in lipopoly-
saccharide (LPS)-induced lung endothelial barrier dysfunction and lung injury in vivo. Both cultured
human pulmonary artery endothelial cells (HPAECs) and experimental animals [AMPK subunit
aedeﬁcient mice and wild-type (WT) control mice (C57BL/6J)] were used. In cultured HPAECs, LPS
increased endothelial permeability in parallel with a decrease in AMPK activity. Consistent with this
observation, AMPK activation with the potent AMPK activator 5-aminoimidazole-4-carboxamide-1-D-
ribofuranoside (AICAR) attenuated LPS-induced endothelial hyperpermeability in vitro. Intratracheal
administration of LPS (1 mg/kg) in WT mice reduced AMPK phosphorylation at Thr172 in lung tissue
extracts, increased protein content and cell count in bronchial alveolar lavage ﬂuid, and increased
Evans Blue dye inﬁltration into the lung. These same attributes were similarly enhanced in AMPKa-
knockout mice, compared with WT mice. Pretreatment with AICAR reduced these lung injury indicators
in LPS-treated WT mice. AMPK activation with AICAR attenuated LPS-induced endothelial hyper-
permeability by activating the Rac/Cdc42/PAK pathway, with concomitant inhibition of the Rho
pathway, and decreased VE-cadherin phosphorylation at Tyr658. We conclude that AMPK activity
supports normal endothelial barrier function and that LPS exposure inhibits AMPK, thereby contributing
to endothelial barrier dysfunction and lung injury. (Am J Pathol 2013, 182: 1021e1030; http://
dx.doi.org/10.1016/j.ajpath.2012.11.022)Supported by NIH grants HL079584, HL080499, HL074399, HL089920,
HL096032, HL105157, and HL110488 (M.-H.Z.), a research award from the
American Diabetes Association (M.-H.Z.), funds from theWarren Chair of the
University of OklahomaHealth Sciences Center, and funds from the American
Heart Association national established investigator award (all to M.-H.Z.).Vascular endothelial permeability plays a pivotal role in
regulating many physiological and pathological processes,
including angiogenesis, immunity, and inﬂammation.1 In
lungs, endothelial cells form a semipermeable barrier
between the vessel lumen and underlying alveoli, thereby
mediating the transmigration of blood cells and maintaining
ﬂuid homeostasis. The integrity of the endothelial cell (EC)
monolayer therefore directly determines lung vascular
permeability. For example, EC barrier dysfunction can lead
to an increase in permeation of ﬂuid and macromolecules into
the interstitium and alveolar space, resulting in pulmonary
edema, a major characteristic of acute lung injury.
RhoA, Rac1, and Cdc42 are key members of the Rho
GTPase family and are activated on binding GTP at the
membrane.2 These proteins are intimately involved instigative Pathology.
.regulating cell adhesion and cytoskeletal dynamics, both
of which play an important role in endothelial barrier
function.3e5 For example, Rac1 and Cdc42 are important in
maintaining, stabilizing, and restoring the endothelial
barrier.3 More speciﬁcally, Baumer et al6 demonstrated that
Rac1 is involved in mitigating endothelial hyperpermeability
by a subset of agonists, including thrombin and lipopoly-
saccharide (LPS). In addition, activation of the Rho GTPases
Cdc42 and Rac1 restores endothelium integrity after lung
injury.7 Although the contributions of Rho GTPases in
Xing et almaintaining endothelial barrier function are well established,
how Rho GTPase is regulated in endothelial cells is largely
unknown.
AMP-activated protein kinase (AMPK) is a hetero-
trimeric serine/threonine kinase; a catalytic a subunit and
regulatory b and g subunits are important in maintaining the
stability of the complex. AMPK belongs to a family of
energy-sensing enzymes that function as fuel gauges,
monitoring changes in the energy status of the cell.8 AMPK
is activated in response to a variety of stressors that increase
the intracellular ratio of AMP to ATP. On activation,
AMPK phosphorylates a number of downstream targets,
thereby affecting glucose metabolism, fatty acid oxidation,
hepatic lipogenesis, and cholesterol synthesis.9 In addition
to its regulatory role in metabolism, recent studies have
demonstrated a role for AMPK in maintaining normal
endothelial function.10 For example, AMPK subunit a2
exerts protective effects against atherosclerosis by inhibiting
the endoplasmic reticulum stress response in ECs.11 Thus,
agents that enhance EC barrier function are of potential
therapeutic value in a variety of pathological settings,
including inﬂammatory disease, atherosclerosis, and tumor
angiogenesis. The effects of AMPK on endothelial barrier
function and vascular permeability have not been investi-
gated previously. Thus, the aim of the present study was to
investigate whether AMPK protects lung endothelial barrier




also known as acadesine) was purchased from Toronto
Chemicals (Toronto, ON, Canada). The Rac1 inhibitor NSC
23766 was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibodies against Thr172-phosphorylated
AMPKa, AMPKa, Ser307-phosphorylated LKB1, Ser79-
phosphorylated acetyl coenzyme A carboxylase (ACC),
vascular endothelial cadherin (VE-cadherin), and diphos-
phorylated myosin light chain (pp-MLC Thr18/Ser19) were
purchased from Cell Signaling Technology (Danvers, MA).
Antibody against LKB1 was purchased from Santa Cruz
Biotechnology. Tyr658-phosphorylated VE-cadherin was
purchased from Calbiochem (San Diego, CA). Texas Red
phalloidineconjugated and Alexa Fluor 488econjugated
secondary antibodies were purchased from Invitrogen
(Carlsbad, CA). Bacterial LPS (Escherichia coliO55:B5)was
purchased from Sigma-Aldrich (St. Louis, MO). Unless
otherwise speciﬁed, all biochemical reagents were purchased
from Sigma-Aldrich.
Animals
Knockout (KO) mice lacking AMPK subunit a1 (a1-KO)12
or AMPK subunit a2 (a2-KO)13 and their wild-type (WT)1022genetic controls were used. The two subunits are encoded
by Prkaa1 and Prkaa2 (synonyms: Ampka1 and Ampka2).
The mice were housed in temperature-controlled cages
under a 12-hour lightedark cycle and were given free access
to water and normal chow. Mice aged 8 to 10 weeks
were used for subsequent experiments. A solution of LPS
(1 mg/kg) in PBS was delivered intratracheally; PBS alone
was used as a control. After 16 hours, bronchoalveolar
lavage was performed by intratracheal injection of 1 mL of
PBS solution, followed by gentle aspiration. The recovered
ﬂuids were processed for determination of total protein
concentration and white blood cell counts. Lungs from
challenged mice were collected for histological evaluation
by H&E staining or were frozen at 80C.
The animal protocol was approved by the University of
Oklahoma Health Sciences Center Institutional Animal Care
and Use Committee.
Evans Blue Staining in Lungs
Accumulation of Evans Blue dye in lung tissue was eval-
uated according to a protocol described previously.14 In
brief, Evans Blue dye (30 mL/kg) was injected into the
external jugular vein 2 hours before sacriﬁce. At the end of
the experiment, a thoracotomy was performed and the lungs
were perfused with PBS containing 5 mmol/L EDTA, to
remove blood. Both left and right lobes of the lung were
excised. Evans Blue accumulation in the lung tissue was
measured by spectroﬂuorometric analysis of lung tissue
lysates according to a protocol described previously.15
Cell Culture
Human pulmonary artery endothelial cells (HPAECs) and n
bovine pulmonary artery endothelial cells (BPAECs) were
purchased from Cell Applications (San Diego, CA). For
subsequent experiments, cell lineswere used at passages 5 to 9.
Rac1/Cdc42 Activity Assay
Cell lysates were immunoprecipitated with PAK-1 PBD
(p21/Cdc42/Rac1-activated kinase p21-binding domain).
Rac1/Cdc42 activation was evaluated using a Rac1/Cdc42
activation assay kit (Millipore, Billerica, MA) according to
the manufacturer’s instructions.
Immunoﬂuorescence Staining
BPAEC monolayers were ﬁxed in 4% paraformaldehyde
solution for 10 minutes, followed by permeabilization with
0.2% Triton X-100 surfactant. After blocking with 1% sodium
borohydrite, cellmonolayerswere incubatedwith antibodies in
blocking solution (2% bovine serum albumin in PBS) for
1 hour, followed by stainingwithAlexaFluor 488econjugated
secondary antibody (Invitrogen, Grand Island, NY). Actin
ﬁlaments were stained with Texas Redeconjugated phalloidinajp.amjpathol.org - The American Journal of Pathology
AMPK and Lung Endothelial Barrierfor 1 hour. All of these steps were performed at room temper-
ature. After the immunostaining, glass slides were prepared
using mounting medium (Santa Cruz Biotechnology, Santa
Cruz, CA) and analyzed using a video-imaging system.
AMPK Activity Assay
Total AMPK was immunoprecipitated from 500 mg of
protein using an antibody against AMPKa. AMPK activity
in immunoprecipitates was assessed by determining the
incorporation of 32P into the synthetic SAMs peptide, as
described previously.9,16
Western Blot Analysis
Western blotting was performed as described previously.17
siRNA Transfection in Endothelial Cells
Transient transfection of siRNA was performed according to
the Santa Cruz Biotechnology protocol. Brieﬂy, the siRNAs
were dissolved in RNAse-free H2O to prepare a 10 mmol/L
stock solution. HPAECs grown in six-well plates were trans-
fected with siRNA in Gibco transfection medium containing
RNAiMax (Invitrogen). For each transfection, 4 mL siRNA in
100 mL transfection medium was gently mixed with 3 mL ofFigure 1 AMPK activation by AICAR attenuates LPS-induced lung vascular lea
(1 mg/kg intratracheal); BALF and lung tissue extracts were collected 16 hours lat
protein concentration in BALF. D: Immunochemical evaluation of lung tissue by H&
assessed by accumulation of Evans Blue dye in the lungs. Lungs were excised afte
and left, respectively). Spectrophotometric analysis of Evans Blueestained albumi
SEM. n Z 4 to 6 per group. *P < 0.05 versus control; yP < 0.05 versus LPS. Co
The American Journal of Pathology - ajp.amjpathol.orgtransfection reagent in 100 mL transfection medium. After 30
minutes of incubation at room temperature, the siRNAelipid
complexes were added to the cells in 0.8 mL transfection
medium. The cells were incubatedwith this mixture for 6 hours
at 37C. After incubation, the transfection medium was
replaced with normal medium, and cells were cultured for 48
hours.Adenoviral Preparation and Infection
Adenoviral vector AMPK-CA (a constitutively active AMPK
mutant) was generated as described previously.18 Adenoviral
vector AMPK-DN (a dominant-negative mutant of AMPK)
was generated by subcloning the cDNA encoding AMPKa1-
DN-(D159A) into adenoviral vector pAdEasy-1. Conﬂuent
cells were infected with adenoviruses as described previ-
ously.18Adenovirus encodingGFPwasused as control.Under
these conditions, efﬁciency of GFP expression was >80%.Statistical Analysis
Data are expressed asmeansSEM. Statistical analyseswere
performed using Student’s t-test (two groups) or one-way
analysis of variance followed by the Bonferroni procedure
for multiple comparison tests (three or more groups), usingkage. AICAR (500 mg/kg i.p.) was injected 4 hours before injection of LPS
er. A: Phosphorylation of AMPK at Thr172 in lungs. B and C: Cell counts and
E staining (original magniﬁcation 40). E: Lung vascular permeability was
r perfusion and imaged. Each panel shows the right and left lungs (at right
n content in the lung tissues was quantiﬁed. Data are expressed as means 
n, control.
1023
Xing et alGraphPad Prism software version 4 (GraphPad Software, San
Diego, CA). A P value of 0.05 was considered signiﬁcant.
Results
LPS Inhibits AMPK in Vivo
Because AMPK is important in maintaining normal endo-
thelial function and because LPS treatment results in
endothelial barrier dysfunction, we investigated whether
LPS increases endothelial permeability through modulating
AMPK. WT mice treated with LPS had signiﬁcantly
reduced levels of Thr172-phosphorylated AMPK (activated)
in lung tissue, compared with untreated mice (Figure 1A).
This suggests a role for LPS as an inhibitor of AMPK
activity in vivo.
LPS Causes Endothelial Barrier Dysfunction in Vivo
We then investigated the effect of LPS treatment on endo-
thelial barrier function in WT mice. Lung EC barrier
dysfunction is characterized by increased permeation of
ﬂuid and macromolecules into the interstitium and alveolar
space. Compared with that of control mice, LPS treatment
induced a ﬁvefold increase in the white blood cell count
within the bronchoalveolar lavage ﬂuid (BALF), which is
indicative of an acute inﬂammatory response in the lungs
(Figure 1B). LPS consistently induced a signiﬁcant increase
in the total protein concentration in BALF (Figure 1C),
indicating barrier disruption and lung injury. Histological
examination of lung tissue from LPS-treated mice revealed
enhanced alveolar wall thickening and inﬁltration of whiteFigure 2 AMPK deletion increases LPS-induced lung vascular leakage and inﬂa
LPS (1 mg/kg intratracheal); lung tissue and BALF were collected 16 hours later.
concentrations and BALF cell counts D: Immunochemical evaluation of lung tissue
KO mice were injected with AICAR (500 mg/kg i.p.); after 4 hours, the mice w
collected 16 hours later. Data are expressed as means  SEM. *P < 0.05 versus
1024blood cells into the lung interstitium and alveolar spaces
(Figure 1D). LPS injection caused inﬁltration of Evans
Blueestained albumin from the vessel into the lung tissue,
further substantiating the effect of LPS on EC barrier
dysfunction (Figure 1E).
AMPK Depletion Accentuates LPS-Induced Acute Lung
Injury in Vivo
Because LPS suppressed AMPK activity in vivo (Figure 1A),
we next determined whether AMPK deletion accentuates
LPS-induced hyperpermeability and lung injury. Lung injury
was analyzed in both WT and AMPKa-KO mice challenged
with LPS. The predominant AMPKa subunit found in lungs
was a1 (Figure 2A). After LPS treatment, BALF protein
levels and cell counts were higher in AMPKa-KO mice than
in WTmice (Figure 2, B and C). Consistent with this ﬁnding,
inﬁltration of inﬂammatory cells into lung tissue, lung
congestion, and edema were also more severe, especially in
a1-KO mice (Figure 2, BeD).
AMPK Activation Attenuates LPS-Induced Endothelial
Barrier Dysfunction in Vivo
We next investigated the effects of AICAR in AMPKa-
deﬁcient mice, to exclude potential off-target effects of this
drug. AICAR alone did not alter the basal level of Evans
Blueestained albumin extravasation and inﬂammatory cell
inﬁltration in control WT mice (Figure 1, D and E); however,
AICAR treatment signiﬁcantly attenuated LPS-induced micro-
vascular lung leakage (Figure 1E) and decreased BALFmmation. WT, a1-KO (a1/), and a2-KO (a2/) mice were injected with
A: Levels of total AMPKa, AMPKa1, and AMPKa2 in lungs. B and C: Protein
by H&E staining (original magniﬁcation 10). E and F: WT, a1-KO, and a2-
ere injected with LPS (1 mg/kg intratracheal); lung tissue and BALF were
WT. AIC, AICAR. n Z 6 per group.
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Figure 3 AMPK activation with AICAR attenuates LPS-induced endo-
thelial barrier disruption. A and B: Effects of AICAR on LPS-induced F-actin
and VE-cadherin. BPAECs grown on glass coverslips were treated with
1 mmol/L AICAR for 1 hour before 200 ng/mL LPS challenge. Cytoskeletal
remodeling was analyzed by double-immunoﬂuorescence staining with VE-
cadherin (green) and Texas Red phalloidin. C: BPAECs were infected with
adenovirus AMPK-DN or AMPK-CA for 36 hours; adenovirus GFP served as
control. Infected BPAECs were then treated with 200 ng/mL LPS for 6 hours.
Paracellular gaps are indicated by arrows. Original magniﬁcation 100.
AMPK and Lung Endothelial Barrierprotein concentration (Figure 1C). Furthermore, AICAR did
not attenuate the decrease of BALF protein concentration and
cell count in LPS-treated a1-KO or a2-KO mice (Figure 2,
E and F).
LPS Disrupts EC Barrier Function and Increases
Endothelial Hyperpermeability in Cultured BPAECs
EC cytoskeletal rearrangement causes formation of gaps
between cells and increases endothelial permeability. We
therefore examined whether LPS alters cytoskeletal rear-
rangement in cultured BPAECs. In unstimulated cells,
F-actin was primarily organized into actin bundles and
cortical actin structures were more diffuse (Figure 3A).
After stimulation with 200 ng/mL LPS, F-actin reorganized
into thicker stress ﬁbers in the center of cells, whereas
peripheral actin bands were weakened (Figure 3A). These
changes were associated with the appearance of paracellular
gaps, indicating EC barrier disruption by LPS.
Activation of AMPK Attenuates LPS-Induced
Endothelial Hyperpermeability in Cultured HPAECs
and BPAECs
We next determined the effects of AICAR on LPS-induced
disruption of endothelial barrier function in culturedHPAECs.
AICAR did not affect cytoskeletal rearrangement in unsti-
mulated HPAECs; however, AICAR pretreatment attenuated
LPS-induced stress ﬁber and gap formation (Figure 3, A and
B). AMPK-CA attenuated LPS-induced cytoskeletal rear-
rangement, compared with control (Figure 3C). Conversely,
AMPK-DN-infected BPAECs exhibited increased stress ﬁber
and gap formation, compared with control (Figure 3C).
Consistent with this ﬁnding, AICAR decreased the phos-
phorylation of VE-cadherin at Tyr658 in a dose- and time-
dependent manner (Figure 4, A and B). Inhibition of
AMPKa1 or AMPKa2 increased the phosphorylation of
VE-cadherin at Tyr658 (Figure 4C).
AICAR Inhibits LPS-Induced MLC Phosphorylation
The balance between Rho and Rac pathways controls endo-
thelial permeability. To determine whether AICAR affects
the Rho signaling pathway, we ﬁrst tested MLC, a well-
established downstream target of Rho pathway. AICAR
inhibited LPS-induced phosphorylation ofMLC (Figure 4D).
LPS Inhibits AMPK Phosphorylation at Thr172 and
AMPK Activity in HPAECs
Thr172 is located in the activation loop of the AMPK a1
and a2 subunits, and its phosphorylation leads to AMPK
activation.19 Our in vivo data (Figure 1A) suggested a role
for LPS in AMPK phosphorylation at Thr172. To conﬁrm
this hypothesis, we exposed conﬂuent HPAECs (an estab-
lished EC model) to LPS for 0.2, 0.5, 1, 2, and 6 hours.The American Journal of Pathology - ajp.amjpathol.orgAMPK phosphorylation at Thr172 was detected by Western
blotting. LPS inhibited phosphorylation of both AMPK at
Thr172 and its downstream kinase, acetyl coenzyme A
carboxylase (ACC) at Ser79 (Figure 5A). Consistent with1025
Figure 4 Activation of AMPK by AICAR decreases phosphorylation of both VE-cadherin (at Tyr658) and
MLC. A and B: Dose- and time-dependent effects of AICAR on VE-cadherin phosphorylation at Tyr658. HPAECs
were treated with 0.1 to 2.0 mmol/L AICAR for 1 hour or were treated with AICAR at 1 mmol/L for 5 to 120
minutes. C: Immunoblot analysis of VE-cadherin phosphorylation at Tyr658 in HPAECs transfected with
AMPKa1 or AMPKa2 siRNA. HPAECs were transfected with control siRNA, AMPKa1 siRNA, or AMPKa2 siRNA for
48 hours, then treated with AICAR for 1 hour. Cell lysates were subjected to Western blot analysis using
antibodies against p-VE-cadherin, VE-cadherin, AMPKa1, and AMPKa2. D: Effects of AICAR on the phos-
phorylation of MLC in HPAECs. HPAECs were pretreated with 1 mmol/L AICAR for 1 hour and then challenged
with 200 ng/mL LPS for 1 or 6 hours. Cell extracts were analyzed for levels of pp-MLC (phosphorylated at both
Thr18 and Ser19). Blots are representative of three independent experiments.
Xing et althis ﬁnding, LPS decreased AMPK activity as early as
30 minutes after LPS exposure (Figure 5B).
LPS Increases LKB1 Phosphorylation at Ser307
We next determined whether LPS inhibits AMPK by
altering phosphorylation of its upstream kinase LKB1 at
Ser307. LPS increased LKB1 phosphorylation at Ser307
(Figure 5C), and therefore the inhibitory effects of LPS on
AMPK are independent of LKB1.
LPS Has No Effect on PP2C Expression in HPAECs
Because protein phosphatase 2C (PP2C) dephosphorylates
AMPK in response to inﬂammatory mediators such as TNFa,1026we determined the effects of LPS on PP2C expression in our
system. LPS did not affect PP2C expression in either a dose-
dependent or a time-dependent manner (Figure 5, D and E).
AICAR Reduces LPS-Induced AMPK Inhibition
Conﬂuent HPAECs were treated with AICAR in a dose- and
time-dependent manner, after which AMPK and ACC phos-
phorylation were detected via Western blotting. The levels of
Thr172-phosphorylated AMPK signiﬁcantly increased in
response to AICAR (0.1 to 2 mmol/L) in a dose-dependent
manner (Figure 6A). Using 1.0 mmol/L as the optimal
concentration of AICAR, we assessed the time course over
120 minutes for AMPK and ACC phosphorylation. Increased
phosphorylation of AMPK at Thr172 and of ACC at Ser79Figure 5 Effects of LPS on the phosphorylation of
AMPK and LKB in HPAECs. A: Effects of LPS on the
phosphorylation of AMPK at Thr172 and ACC at Ser79
in HPAECs. HPAECs were treated with 200 ng/mL LPS
for 0.2 to 6 hours. Cell extracts were analyzed for
levels of Thr172-phosphorylated AMPK and Ser79-
phosphorylated ACC by Western blotting B: Effects
of LPS on AMPK activity. HPAECs were treated with
200 ng/mL LPS for 0.5 to 6 hours. AMPK activity was
assayed as described under Materials and Methods. C:
Effects of LPS on LKB1 phosphorylation in HPAECs.
HPAECs were treated with 200 ng/mL LPS for 0.2 to
6 hours. Cell extracts were analyzed for LKB1 phos-
phorylation at Ser307. D and E: Dose- and time-
dependent effects of LPS on PP2C expression.
HPAECs were treated with LPS at 0.05 to 5 mg/mL for
1 hour or at 1.0 mg/mL for 0.2 to 6 hours. Cell extracts
were analyzed for levels of PP2C by Western blotting.
Data are expressed as means  SEM. nZ 3 per group.
*P < 0.05 treated versus untreated control. Blots are
representative of three independent experiments.
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Figure 6 AICAR activates AMPK-ACC pathways in HPAECs. A: Dose-dependent phosphorylation of AMPK by AICAR. HPAECs were stimulated with AICAR at
0.1 to 2 mmol/L for 1 hour. B: Time-dependent phosphorylation of AMPK by AICAR. HPAECs were stimulated for 5 to 120 minutes with 1 mmol/L AICAR. C:
HPAECs were pretreated with 1 mmol/L AICAR for 30 minutes and then treated with LPS for 1 or 6 hours. Data are expressed as means  SEM. nZ 3 per group.
*P < 0.05 versus control; yP < 0.05 versus LPS group. Blots are representative of three independent experiments.
Figure 7 AMPK Regulates RAC/Cd42 signaling. Effects of AICAR on
levels of Rac-GTP (A) and Cdc42 (B) in HPAECs. HPAECs were treated
with 1 mmol/L AICAR for 10, 30, or 60 minutes. Rac and Cdc42 were
analyzed by pull-down assays. Data are expressed as means  SEM. *P <
0.05 versus control. Blots are representative of three independent
experiments.
AMPK and Lung Endothelial Barrierwas detected after 15 minutes and peaked at the 60-minute
time point (Figure 6B). Importantly, AICAR prevented the
LPS-induced reduction in phosphorylation of AMPK at
Thr172 and of ACC at Ser79 (Figure 6C).
AICAR Activates Rac1/Cdc42
We next determined the mechanism or mechanisms by
which AMPK activation by AICAR prevents LPS-induced
cytoskeletal rearrangement. Activated Rho family members
Cdc42 and Rac1 regulate endothelial barrier function,3e5 by
re-establishing EC junction integrity after injury.7 We
therefore investigated the effects of AICAR on Rac1/Cdc42
in HPAECs. AICAR activated both Rac1 and Cdc42 in
a time-dependent manner (Figure 7, A and B). These results
indicate AMPK-dependent activation of Rac1 and Cdc42.
PAK Is Involved in AICAR-Mediated Rac1/Cdc42
Signaling
To further corroborate the role of AICAR in the Rac1-
mediated signaling pathway, we assessed the effects of
AMPK on PAK, a downstream target of Rac1 that plays
a crucial role in cell motility, cytoskeletal remodeling, cell
contraction, and barrier regulation.14 AICAR increased PAK
phosphorylation in HPAECs in a dose- and time-dependent
manner (Figure 8, A and B). Consistent with this ﬁnding,
inhibition of AMPKa1 or AMPKa2 with siRNA led to
a reduction in p-PAK (Figure 8C). When HPAECs were pre-
treated with the Rac inhibitor NSC 23766 or with Rac siRNA
(Figure 8, D and E), PAK phosphorylation decreased, which
conﬁrms PAK as a downstream target for Rac1 in our system.
Discussion
Themajorﬁnding of the present study is thatAMPK inhibition
contributes to LPS-induced endothelial barrier dysfunctionThe American Journal of Pathology - ajp.amjpathol.organd lung injury. LPS inhibited AMPK activity both in vitro
and in vivo. Importantly, lung tissue inﬂammatory cell inﬁl-
tration, lung congestion, and edema were more severe in
AMPKa-deﬁcientmice than inWTmice, especially ina1-KO
mice, suggesting that AMPK deletion accentuates lung
endothelial barrier dysfunction and lung injury in vivo.
AICAR, which activates AMPK in the lungs, decreased
pulmonary vascular permeability and diminished the severity1027
Figure 8 Regulation of PAK signaling by AMPK. A: Dose-dependent induction of PAK phosphorylation by AICAR. HPAECs were stimulated with 0.05 to
2.0 mmol/L AICAR for 1 hour. B: Time-dependent increase in PAK phosphorylation in HPAECs by 1 mmol/L AICAR treatment. HPAECs were stimulated for 5 to
120 minutes with 1 mmol/L AICAR. Protein cell lysates (20 mg) were analyzed by immunoblotting using antiep-PAK and anti-PAK antibodies. C: PAK
phosphorylation in HPAECs transfected with AMPKa1 or AMPKa2 siRNA. HPAECs were transfected with control siRNA, AMPKa1 siRNA, or AMPKa2 siRNA for 48
hours, and then treated with 1 mmol/L AICAR for 1 hour. Cell lysates were subjected to Western blot analysis using antibodies against p-PAK, AMPKa1, or
AMPKa2. D and E: Inhibition of Rac on phosphorylation of PAK in HPAECs. HPAECs were treated with 1 mmol/L AICAR, with or without 100 mmol/L NSC 23766,
for 1 hour. HPAECs were transfected with control siRNA, Rac siRNA for 48 hours, and then treated with 1 mmol/L AICAR for 1 hour. Cell lysates were subjected
to Western blot analysis using antibodies against p-PAK. Data are expressed as means  SEM. n Z 3 per group. *P < 0.05 versus control; yP < 0.05 versus
AICAR. Blots are representative of three independent experiments.
Xing et alof LPS-induced acute lung injury. LPS-induced lung injury
was more severe in AMPKa-KO mice, indicating that
AMPKa is important in maintaining endothelial integrity.
Thus, AMPK activation by AICAR attenuates LPS-induced
pulmonary vascular hyperpermeability and lung injury.
The effect of AMPK on maintaining endothelial integrity
appears to be mediated by multiple pathways. For example,
the ability of AMPK activation to enhance pulmonary
vascular barrier function appears to be related to its asso-
ciation with cytoskeletal organization, including enhance-
ment of microtubule and actin polymerization. Our data
show that AMPK-induced Rac/Cdc42 activation leads to
activation of the Rac downstream target PAK, which plays
a crucial role in cell motility, cytoskeletal remodeling, cell
contraction, and barrier regulation.14 Also, activation of the
Rac pathway indirectly inhibits Rho signaling.20 AICAR
activated Rac and Cdc42, but inhibited LPS-induced phos-
phorylation of MLC, a downstream target of Rho, thus
inhibiting LPS-induced disruption of the cell cytoskeleton
and cell adhesion. Wu and colleagues21 suggest that the
protein stability, localization, and phosphorylation of VE
cadherin play critical roles in maintaining cell-to-cell junc-
tions. Our data indicate that AICAR decreases VE-cadherin1028phosphorylation at Tyr658, a key regulatory site of endo-
thelial barrier function,22 thereby leading to the inhibition of
cell barrier function.23,24 Conversely, inhibition of
AMPKa1 or AMPKa2 increased VE-cadherin phosphory-
lation at Tyr658. Alternatively, the protective effects of
AMPK on endothelial permeability may be due, in part, to
its anti-inﬂammatory activities and antioxidative stress
effects,10,25,26 as suggested previously.27
The mechanism or mechanisms by which LPS inhibits
AMPK remain unknown. Evidence suggests that inﬂam-
matory mediators such as TNFa up-regulate phosphatase
PP2C, which results in dephosphorylation of AMPK,
thereby decreasing its activity.26,28 In the present study,
however, LPS did not alter the levels of PP2C. Moreover,
LPS-induced AMPK inhibition does not appear to be related
to LKB1, an upstream kinase of AMPK. In fact, LPS treat-
ment increased the phosphorylation of LKB1 at Ser307,
a phosphorylation site known to be important for AMPK
activation.29 LKB1 is reported to regulate lung cancer cell
polarity by mediating Cdc42 recruitment and activity.30 In
addition, PAK phosphorylation is impaired in cell lines (eg,
the human lung adenocarcinoma epithelial cell line A549)
in which LKB1 function is naturally lost.30,31 Whetherajp.amjpathol.org - The American Journal of Pathology
AMPK and Lung Endothelial Barrierthis effect of LKB1 is mediated by AMPK warrants further
investigation.
In summary, the present study yielded three novel ﬁnd-
ings: i) activation of AMPK protects against lung barrier
dysfunction and neutrophil accumulation induced by intra-
tracheal LPS challenge; ii) protective effects of AMPK
against LPS-induced lung dysfunction are mediated by lung
vascular endothelium and controlled by Rac GTPase effector
PAK1 and tyrosine phosphorylation of VE-cadherin; and iii)
LPS inhibits endogenous AMPK expression in the lung. In
addition to the endothelial effects described here, AMPKmay
engage other mechanisms (eg, anti-inﬂammatory or antioxi-
dant). AMPK activation may serve as a potentially useful
therapeutic strategy for treating diseases characterized by
high permeability states.
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